M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Lenvatinib with Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Phase 2

Active, not recruiting

Conditions: Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC V8
Stage IV Renal Cell Cancer AJCC V8

Interventions: Drug: Cabozantinib
Drug: Everolimus
Other: Questionnaire Administration
Drug: Lenvatinib

First Posted Date: 2021-08-19

Last Posted Date: 2024-10-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT05012371

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Decitabine and Cedazuridine
Drug: Gilteritinib
Drug: Venetoclax

First Posted Date: 2021-08-18

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT05010122

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Recruiting

Conditions: Central Nervous System Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Leukemia
Plasma Cell Myeloma
Secondary Central Nervous System Lymphoma
Lymphoma

Interventions: Procedure: Magnetic Resonance Imaging
Other: Neurocognitive Assessment
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-08-18

Last Posted Date: 2024-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05011045

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation

Phase 1

Recruiting

Conditions: Stage IIIA Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Locally Advanced Lung Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8

Interventions: Procedure: 6 Minute Walk Functional Test
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Exercise Cardiac Stress Test
Other: Questionnaire Administration
Procedure: Single Photon Emission Computed Tomography

First Posted Date: 2021-08-18

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05010109

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Recurrent Malignant Solid Neoplasm
Metastatic Malignant Neoplasm in the Bone
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions: Drug: Copanlisib
Drug: Elimusertib

First Posted Date: 2021-08-18

Last Posted Date: 2022-05-27

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05010096

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Decitabine and Cedazuridine
Drug: Venetoclax
Drug: Gilteritinib
Drug: Enasidenib
Drug: Ivosidenib

First Posted Date: 2021-08-18

Last Posted Date: 2025-01-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 125

Registration Number: NCT05010772

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Phase 2

Recruiting

Conditions: Chronic Phase Chronic Myelogenous Leukemia
Philadelphia Chromosome Positive
BCR-ABL1 Positive
BCR-ABL1 Positive Chronic Myelogenous Leukemia

Interventions: Drug: Dasatinib
Drug: Decitabine and Cedazuridine

First Posted Date: 2021-08-17

Last Posted Date: 2024-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT05007873

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Comparing the Performance of Automated Breast Ultrasonography to Hand-Held Whole Breast Ultrasonography in Breast Cancer Treatment Response Assessment

Withdrawn

Conditions: Breast Carcinoma

Interventions: Procedure: Ultrasonography

First Posted Date: 2021-08-16

Last Posted Date: 2022-05-27

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05005936

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule

Not Applicable

Recruiting

Conditions: Recurrent Thyroid Gland Carcinoma
Thyroid Gland Follicular Tumor of Uncertain Malignant Potential
Benign Thyroid Gland Neoplasm
Thyroid Gland Nodule
Thyroid Gland Papillary Carcinoma

Interventions: Other: Quality-of-Life Assessment
Procedure: Radiofrequency Ablation

First Posted Date: 2021-08-12

Last Posted Date: 2024-10-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT05003856

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Contemporary Characteristics of Penile Cancer

Recruiting

Conditions: Squamous Cell Carcinoma of the Penis
Penile Carcinoma

Interventions: Other: Data Capture
Other: Questionnaire Administration

First Posted Date: 2021-08-09

Last Posted Date: 2024-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1000

Registration Number: NCT04996849

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy